多発性硬化症治療薬の世界市場規模調査＆予測：薬物クラス別、投与経路別、流通チャネル別、地域別分析、2022-2029年

多発性硬化症は、脳や脊髄の神経細胞を侵し、軸索切断、脱髄、神経変性を引き起こす炎症性免疫介在性疾患です。

最もよく使われる治療法には、理学療法、筋弛緩剤、抗うつ剤、経口薬、注射薬、点滴薬などがあります。フマル酸ジメチル、テリフルノミド、クラドリビンなどの経口薬、オクレリズマブなどの点滴療法、インターフェロン-β、グラチラマーアセテートなどの筋肉内または皮下投与による注射療法があります。市場成長の主な要因は、多発性硬化症の有病率の上昇と、市場開拓のための研究開発投資の増加であり、予測期間中の市場成長をサポートすると予想されます。

国際多発性硬化症連合（MSIF）によると、全世界の多発性硬化症患者数は、2013年の230万人から2020年には280万人に増加するとされています。同疾患の有病率の上昇に伴い、効果的な多発性硬化症の診断と治療に対する需要は世界中で高まっています。また、市場関係者による研究開発や臨床試験の活発化も、同市場の有利な需要を生み出すと考えられます。例えば、非再発性二次性進行性MS（nrSPMS）、再発性MS（RMS）、原発性進行性MSの治療のために、サノフィはトレブルチニブ（PPMS）の第III相臨床試験を実施しています。サノフィは、承認された適応症について、それぞれ2024年および2025年以上にこの薬を提出することを予想しています。さらに、多発性硬化症の治療に対する政府支援の高まりは、予測期間中の市場成長を高めると考えられます。しかし、多発性硬化症治療薬の高コストが、2022-2029年の予測期間を通じて市場成長を阻害します。

多発性硬化症治療薬の世界市場調査において考慮された主要地域は、アジア太平洋地域、北米、欧州、中南米、その他の地域です。北米は、研究開発投資の増加、新製品開拓、免疫抑制剤および分子抗体医薬品の需要拡大により、市場シェアで世界的に優位な地域となっています。一方、アジア太平洋地域は、多発性硬化症の有病率の増加や、治療費削減のための政府の取り組みがいくつかの国で活発化しているなどの要因から、予測期間中に高い成長率を示すと予想されています。

市場における最近の開発

• 2021年3月、ヤンセン・ファーマシューティカル社は、再発型MSの人々を治療するための経口特異的スフィンゴシン-1-リン酸受容体1（S1P1）モジュレーターであるPonvoryの米国FDA承認を明らかにしました。Aubagioと比較して、Ponvoryは年間再発率を低下させる効果がより高いです。同社は、本製品をポートフォリオに加えることで、MS治療薬の製品ラインナップを増やしました。

世界市場レポートの範囲

• 過去データ：2019-2020-2021年
• 推計の基準年：2021年
• 予測期間：2022-2029年
• レポート範囲：収益予測、企業ランキング、競合情勢、成長要因、動向
• 地域別範囲：北米、欧州、アジア太平洋地域、ラテンアメリカ、世界のその他地域
• カスタマイズの範囲：レポートカスタマイズ（最大8名分の作業時間）を無料で提供。国別、地域別、セグメント別範囲の追加・変更。

本調査の目的は、近年における様々な分野・国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国の産業の質的・量的な側面を取り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢などの詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

• マーケットスナップショット
• 世界・セグメント別市場推定・予測、2019年～2029年
  • 多発性硬化症治療薬市場、地域別、2019-2029年
  • 多発性硬化症治療薬市場、薬効クラス別、2019-2029年
  • 多発性硬化症治療薬市場、投与経路別、2019-2029年
  • 多発性硬化症治療薬市場、流通チャネル別、2019-2029年
• 主な動向
• 調査手法
• 調査の前提条件

第2章 多発性硬化症治療薬の世界市場の定義とスコープ

• 調査目的
• 市場の定義と範囲
  • 調査対象範囲
  • 産業の進化
• 調査対象年
• 通貨換算レート

第3章 多発性硬化症治療薬の世界市場ダイナミクス

• 多発性硬化症治療薬市場のインパクト分析（2019年～2029年）
  • 市場促進要因
    • 多発性硬化症疾患の有病率の上昇
    • 成長する研究開発投資
  • 市場の課題
    • 多発性硬化症治療薬の高価格化
  • マーケットオポチュニティ
    • 多発性硬化症の治療に対する政府の支援の高まり

第4章 多発性硬化症治療薬の世界市場産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
• PEST分析
  • 政治的
  • 経済的
  • ソーシャル
  • テクニカル
• 最高の投資機会
• 主要成功戦略
• 業界関係者見通し
• アナリストの提言と結論

第5章 リスクアセスメントCOVID-19の影響

• COVID-19が業界に与える全体的な影響についての評価
• COVID-19以前とCOVID-19以後の市場シナリオ

第6章 多発性硬化症治療薬の世界市場：薬物クラス別

• マーケットスナップショット
• 多発性硬化症治療薬の世界市場：薬物クラス別、パフォーマンス-ポテンシャル分析
• 多発性硬化症治療薬の世界市場薬剤クラス別推定・予測2019-2029
• 多発性硬化症治療薬市場、サブセグメント別分析
  • 免疫調節剤
  • 免疫抑制剤
  • インターフェロン

第7章 多発性硬化症治療薬の世界市場：投与経路別

• マーケットスナップショット
• 多発性硬化症治療薬の世界市場：投与経路別、パフォーマンス-ポテンシャル分析
• 多発性硬化症治療薬の世界市場推計・予測（投与経路別） 2019-2029
• 多発性硬化症治療薬市場、サブセグメント別分析
  • オーラル
  • インジェクション

第8章 多発性硬化症治療薬の世界市場：流通チャネル別

• マーケットスナップショット
• 多発性硬化症治療薬の世界市場：流通チャネル別、パフォーマンス-ポテンシャル分析
• 多発性硬化症治療薬の世界市場推計・予測（流通チャネル別） 2019-2029
• 多発性硬化症治療薬市場、サブセグメント別分析
  • 病院薬局
  • リテールファーマシー
  • オンラインファーマシー

第9章 多発性硬化症治療薬の世界市場：地域別分析

• 多発性硬化症治療薬市場、地域別マーケットスナップショット
• 北米
  • 米国
    • 薬剤クラス別の推定・予測、2019年～2029年
    • 投与経路別の推定・予測、2019年～2029年
    • 流通チャネル別の推定・予測、2019年～2029年
  • カナダ
• 欧州の多発性硬化症治療薬市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋地域の多発性硬化症治療薬市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの多発性硬化症治療薬市場スナップショット
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域
• 世界のその他の地域

第10章 競合情報

• トップ市場戦略
• 企業プロファイル
  • Biogen Inc.
    • 主要な情報
    • 概要
    • 財務（データの入手が可能な場合のみ）
    • 製品概要
    • 最近の動向
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Janssen Pharmaceuticals, Inc.（Johnson & Johnson Corporation）
  • Bristol-Myers Squibb Company
  • Cipla Inc.

第11章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • バリデーション
  • 出版
• 調査の特徴
• 調査の前提条件

LIST OF TABLES

• TABLE 1. Global Multiple Sclerosis Drugs Market, report scope
• TABLE 2. Global Multiple Sclerosis Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
• TABLE 3. Global Multiple Sclerosis Drugs Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
• TABLE 4. Global Multiple Sclerosis Drugs Market estimates & forecasts by Route of Administration 2019-2029 (USD Billion)
• TABLE 5. Global Multiple Sclerosis Drugs Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
• TABLE 6. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 7. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 8. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 9. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 10. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 11. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 12. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 13. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 14. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 15. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 16. U.S. Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 17. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 18. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 19. Canada Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 20. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 21. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 22. UK Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 23. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 24. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 25. Germany Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 26. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 27. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 28. France Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 29. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 30. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 31. Italy Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 32. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 33. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 34. Spain Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 35. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 36. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 37. RoE Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 38. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 39. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 40. China Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 41. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 42. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 43. India Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 44. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 45. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 46. Japan Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 47. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 48. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 49. South Korea Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 50. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 51. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 52. Australia Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 53. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 54. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 55. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 56. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 57. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 58. Brazil Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 59. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 60. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 61. Mexico Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 62. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 63. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 64. RoLA Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 65. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 66. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 67. Row Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 68. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 69. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Multiple Sclerosis Drugs Market
• TABLE 71. List of primary sources, used in the study of global Multiple Sclerosis Drugs Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

• FIG 1. Global Multiple Sclerosis Drugs Market, research methodology
• FIG 2. Global Multiple Sclerosis Drugs Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Multiple Sclerosis Drugs Market, key trends 2021
• FIG 5. Global Multiple Sclerosis Drugs Market, growth prospects 2022-2029
• FIG 6. Global Multiple Sclerosis Drugs Market, porters 5 force model
• FIG 7. Global Multiple Sclerosis Drugs Market, pest analysis
• FIG 8. Global Multiple Sclerosis Drugs Market, value chain analysis
• FIG 9. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 10. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 11. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 12. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 13. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 14. Global Multiple Sclerosis Drugs Market, regional snapshot 2019 & 2029
• FIG 15. North America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
• FIG 16. Europe Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
• FIG 17. Asia pacific Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
• FIG 18. Latin America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
• FIG 19. Global Multiple Sclerosis Drugs Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Multiple Sclerosis Drugs Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2022-2029. Multiple sclerosis is an inflammatory immune-mediated disorder that affects nerve cells in the brain and the spinal cord, causing axonal transection, demyelination, and neurodegeneration. Some of the most often used treatments include physical therapy, muscle relaxants, antidepressants, and oral, injectable, and infused medications. Oral drugs including dimethyl fumarate, teriflunomide, and cladribine; intravenous infusion therapies like ocrelizumab; and injectable therapies like interferon-beta, glatiramer acetate, given intramuscularly or subcutaneously. The key factor driving the market growth is rising prevalence of Multiple Sclerosis disease and rising R&D investment by the market players for the drugs development that anticipated to support the market growth during forecast period.

According to the Multiple Sclerosis International Federation (MSIF), the number of patients with multiple sclerosis throughout the globe increased from 2.3 million in 2013 to 2.8 million in 2020. The demand for effective multiple sclerosis diagnosis and treatment has increased worldwide as a result of the disease's rising prevalence. Also, the rising R&D and clinical trial by the market players will create the lucrative demand for the market. For instance, For the therapy of non-relapsing secondary progressive MS (nrSPMS), relapsing forms of MS (RMS), and primary progressive MS, Sanofi is conducting a phase III clinical trial for tolebrutinib (PPMS). Sanofi anticipates submitting this medication in 2024 and 2025+, respectively, for the approved indications. Additionally, the rising government support for the treatment of multiple sclerosis is likely to increase the market growth during the forecast period. However, the high cost of Multiple Sclerosis Drugs stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Multiple Sclerosis Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the rising R&D investment, new product development, and growing demand for immunosuppressant and molecular antibody drugs. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as growing prevalence of multiple sclerosis disease and rising government initiatives in several countries to reduce the cost of treatment would create lucrative growth prospects for the Multiple Sclerosis Drugs market across Asia Pacific region.

Major market players included in this report are:

• Biogen Inc.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck & Co., Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
• Bristol-Myers Squibb Company
• Cipla Inc.

Recent Developments in the Market:

• In March 2021, Janssen Pharmaceutical, Inc. revealed the U.S. FDA approval of Ponvory, an oral specific sphingosine-1-phosphate receptor 1 (S1P1) modulator to treat people with relapsing forms of MS. In comparison to Aubagio, Ponvory is more effective at lowering annual relapse rates. The company increased its range of products for the treatment of MS with the inclusion of this product in its portfolio.

Global Multiple Sclerosis Drugs Market Report Scope:

• Historical Data: 2019-2020-2021

• Base Year for Estimation: 2021

• Forecast period: 2022-2029

• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

• Segments Covered: Drug Class, Route of Administration, Distribution Channel, Region

• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

• Immunomodulators
• Immunosuppressants
• Interferons

By Route of Administration:

• Oral
• Injection

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Multiple Sclerosis Drugs Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Multiple Sclerosis Drugs Market, by Drug Class, 2019-2029 (USD Billion)
  • 1.2.3. Multiple Sclerosis Drugs Market, by Route of Administration, 2019-2029 (USD Billion)
  • 1.2.4. Multiple Sclerosis Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Multiple Sclerosis Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Multiple Sclerosis Drugs Market Dynamics

• 3.1. Multiple Sclerosis Drugs Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising prevalence of multiple sclerosis disease
    • 3.1.1.2. Growing R&D Investment
  • 3.1.2. Market Challenges
    • 3.1.2.1. High cost of multiple sclerosis drugs
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising government support for the treatment of multiple sclerosis

Chapter 4. Global Multiple Sclerosis Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Multiple Sclerosis Drugs Market, by Drug Class

• 6.1. Market Snapshot
• 6.2. Global Multiple Sclerosis Drugs Market by Drug Class, Performance - Potential Analysis
• 6.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
• 6.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
  • 6.4.1. Immunomodulators
  • 6.4.2. Immunosuppressants
  • 6.4.3. Interferons

Chapter 7. Global Multiple Sclerosis Drugs Market, by Route of Administration

• 7.1. Market Snapshot
• 7.2. Global Multiple Sclerosis Drugs Market by Route of Administration, Performance - Potential Analysis
• 7.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
• 7.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
  • 7.4.1. Oral
  • 7.4.2. Injection

Chapter 8. Global Multiple Sclerosis Drugs Market, by Distribution Channel

• 8.1. Market Snapshot
• 8.2. Global Multiple Sclerosis Drugs Market by Distribution Channel, Performance - Potential Analysis
• 8.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
• 8.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Pharmacy

Chapter 9. Global Multiple Sclerosis Drugs Market, Regional Analysis

• 9.1. Multiple Sclerosis Drugs Market, Regional Market Snapshot
• 9.2. North America Multiple Sclerosis Drugs Market
  • 9.2.1. U.S. Multiple Sclerosis Drugs Market
    • 9.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
    • 9.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
    • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
  • 9.2.2. Canada Multiple Sclerosis Drugs Market
• 9.3. Europe Multiple Sclerosis Drugs Market Snapshot
  • 9.3.1. U.K. Multiple Sclerosis Drugs Market
  • 9.3.2. Germany Multiple Sclerosis Drugs Market
  • 9.3.3. France Multiple Sclerosis Drugs Market
  • 9.3.4. Spain Multiple Sclerosis Drugs Market
  • 9.3.5. Italy Multiple Sclerosis Drugs Market
  • 9.3.6. Rest of Europe Multiple Sclerosis Drugs Market
• 9.4. Asia-Pacific Multiple Sclerosis Drugs Market Snapshot
  • 9.4.1. China Multiple Sclerosis Drugs Market
  • 9.4.2. India Multiple Sclerosis Drugs Market
  • 9.4.3. Japan Multiple Sclerosis Drugs Market
  • 9.4.4. Australia Multiple Sclerosis Drugs Market
  • 9.4.5. South Korea Multiple Sclerosis Drugs Market
  • 9.4.6. Rest of Asia Pacific Multiple Sclerosis Drugs Market
• 9.5. Latin America Multiple Sclerosis Drugs Market Snapshot
  • 9.5.1. Brazil Multiple Sclerosis Drugs Market
  • 9.5.2. Mexico Multiple Sclerosis Drugs Market
  • 9.5.3. Rest of Latin America Multiple Sclerosis Drugs Market
• 9.6. Rest of The World Multiple Sclerosis Drugs Market

Chapter 10. Competitive Intelligence

• 10.1. Top Market Strategies
• 10.2. Company Profiles
  • 10.2.1. Biogen Inc.
    • 10.2.1.1. Key Information
    • 10.2.1.2. Overview
    • 10.2.1.3. Financial (Subject to Data Availability)
    • 10.2.1.4. Product Summary
    • 10.2.1.5. Recent Developments
  • 10.2.2. Pfizer Inc.
  • 10.2.3. F. Hoffmann-La Roche Ltd.
  • 10.2.4. Novartis AG
  • 10.2.5. Merck & Co., Inc.
  • 10.2.6. Sanofi S.A.
  • 10.2.7. Teva Pharmaceutical Industries Ltd.
  • 10.2.8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
  • 10.2.9. Bristol-Myers Squibb Company
  • 10.2.10. Cipla Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption